MFN News Items – iZafe Group

Dosell AB Granted European Patent in Data-Driven Medication Management

iZafe Group AB (publ) today announces that its subsidiary Dosell AB has been granted a European patent, EP4228584, titled “Medication Delivery”. The patent strengthens iZafe Group’s long-term position within data-driven and personalized healthcare and represents an important part of the company’s continued development of digital care solutions, including its new remote care system.

The patent covers a system where patient data from sensors is analyzed to identify changes in health status. Based on this information, medication treatment can be adjusted over time, enabling more personalized and proactive care.

Although the patent is not directly linked to Dosell’s current functionality, it aligns with iZafe Group’s strategic direction of combining medical technology, data, and future AI-based analytics.

Through this patent, the company strengthens:

its technological platform for future solutions
its intellectual property value
its position within a growing global healthcare segment

In the long term, the technology enables solutions where treatment can be optimized based on real patient data, contributing to improved patient safety and more efficient healthcare.

“This patent is an important step in our long-term strategy. It clearly demonstrates the direction we are moving in—towards more data-driven, intelligent, and personalized healthcare. At the same time, it strengthens our intellectual property and future potential,” says Anders Segerström, CEO of iZafe Group.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com

Dosell AB Granted European Patent in Data-Driven Medication Management

Dosell Distansvårdssystem

Dosell AB signs framework agreement with Adda following the end of the appeal period

iZafe Group AB (publ) today announces that its subsidiary Dosell AB has signed a framework agreement with Adda Inköpscentral following the conclusion of the appeal period in the national procurement of medication dispensing robots. This enables municipalities and regions across Sweden to procure Dosell through Adda’s framework agreement.

As previously communicated, Dosell was awarded a place in the procurement together with a limited number of suppliers. The procurement represents Sweden’s first national procurement of medication dispensing robots and aims to provide municipalities and regions with a simple and quality assured way to implement digital solutions that enhance patient safety and improve the efficiency of medication management within healthcare and elderly care.

As the framework agreement has now been signed and will enter into force on March 31, municipalities and regions using Adda’s purchasing central will be able to initiate call offs under the agreement.

Interest in medication dispensing robots is increasing as healthcare systems face major challenges related to an ageing population, workforce shortages and the need to strengthen patient safety. Digital solutions such as Dosell can help ensure the right medication at the right time while allowing healthcare staff to use their resources more efficiently.

“The fact that the framework agreement has now been signed means that municipalities across Sweden will have a structured and accessible way to implement Dosell through Adda’s procurement. We see a clear increase in interest in digital solutions for medication management and look forward to contributing to safer and more efficient care together with municipalities and partners,” says Anders Segerström, CEO of iZafe Group.

The framework agreement enables municipalities and regions to conduct call offs during the agreement period in accordance with Adda’s procurement terms.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Dosell AB signs framework agreement with Adda following the end of the appeal period

DSC01573

Communiqué from the Extraordinary General Meeting of iZafe Group AB

An Extraordinary General Meeting was held in iZafe Group AB, reg. no. 556762-3391 (the “Company”), on 12 March 2026 at the Company’s office. The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution of 19 February 2026 regarding a directed issue of up to 39,236,014 class B shares.

The directed share issue constitutes the second part of the capital raise that was announced through a press release on 19 February 2026.

The first part of the directed share issue, comprising 20,868,973 class B shares, which was resolved by the Board of Directors pursuant to the authorization granted by the General Meeting, has already been registered with the Swedish Companies Registration Office (Bolagsverket) and Euroclear Sweden AB.

Through the second part of the directed share issue, which was approved at today’s Extraordinary General Meeting, the Company’s share capital will increase by a maximum of SEK 1,961,800.70 through the issuance of up to 39,236,014 class B shares at a subscription price of SEK 0.33 per class B share.

In total, the Company will receive approximately SEK 19.8 million before transaction costs through the directed share issues.

Following registration of the second part of the directed share issue, which is expected to take place shortly, the number of shares in the Company will amount to 430,591,337 shares, divided into 600,000 class A shares and 429,991,337 class B shares. Following registration of the second part of the directed share issue, the Company’s share capital will amount to SEK 21,529,566.85.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Communiqué from the Extraordinary General Meeting of iZafe Group AB

Business Partners

Monthly Letter February – ADDA, Growth Capital and Preparations for Scaling

February has been a month where several important pieces have fallen into place for iZafe Group. We have been awarded a framework agreement in ADDA’s national procurement of medication dispensing robots and at the same time secured new growth capital to accelerate sales, installations and international expansion.

Over the past few years, we have built a solid foundation with more municipalities, new markets and a growing partner network. With ADDA now in place and a strengthened organization, we are entering the next phase where the focus is on scaling deliveries of Dosell and meeting the increasing demand.

Sweden – ADDA opens the door for broader adoption
The most significant event in February is the award in Sweden’s first national procurement of medication dispensing robots through ADDA. The framework agreement enables municipalities across the country to more easily procure Dosell via ADDA without having to conduct their own full procurement processes.

The standstill period runs until March 10, which means the agreement can be signed on March 11. We see this as an important milestone that creates new opportunities for broader adoption of Dosell in Swedish elderly care.

During the winter, many municipalities have been waiting for this decision before moving forward in their processes. February has therefore been relatively quiet in terms of new agreements, but we see the award decision as crucial for enabling several ongoing dialogues to move forward.

At the same time, some municipalities continue to conduct their own procurements outside ADDA. During February we have worked intensively with several such processes and hope to receive decisions in some of them during March.

Interest from municipalities remains strong. During February we conducted five additional product demonstrations and several tender presentations. We also continue to be contacted directly by municipalities interested in learning more about how Dosell can contribute to safer medication management.

An important milestone during the month is that a municipality previously working with another supplier has been running a pilot with Dosell since November. The outcome has been very positive and the municipality has now placed an order for an additional 40 units, thereby replacing its previous solution.

We have also initiated the onboarding of two new municipalities that will begin their implementations in March. At the same time, we see a clear trend where more municipalities are moving from pilot projects to broader deployment.

Growth capital to accelerate the next phase
During February, a directed share issue of approximately SEK 19.8 million was completed. The capital has been raised to further accelerate the company’s growth.

The new capital will be used, among other things, to strengthen the organization, increase the installation pace of Dosell and meet the growing demand from municipalities and partners. With more markets and an expanding pipeline, the focus is now on ensuring that we have the right resources in place to deliver in line with demand.

The Netherlands – continued scaling
Development in the Netherlands continues steadily and the market shows clear structural growth. During February we held several meetings with healthcare providers on how Dosell can be scaled up following initial implementations.

In the coming months, approximately 30 new departments within existing care providers are expected to begin using Dosell.

We have also completed several integrations, including with the system Bprocare, which simplifies implementation within existing healthcare workflows.

To further strengthen our presence, we have now recruited a Country Manager for the Netherlands. The role will focus on developing both direct sales and partner relationships, while creating a more scalable commercial structure to support continued growth in the market.

Norway – ready for rollout
In Norway, everything is now prepared for the rollout in the six municipalities included in the procurement we previously won together with our partner Vakt og Alarm.

Vakt og Alarm is a committed partner that sees strong potential in Dosell and in how the solution can contribute to more efficient medication management in Norwegian home care. Demand for medication dispensing solutions in Norway is high, and together we see strong opportunities to grow in this market. During February we also submitted a bid in another Norwegian procurement.

Finland, Iceland and Spain
Together with our partners, work also continues in our other markets. In Finland, Iceland and Spain, ongoing activities are underway to develop collaborations, strengthen market presence and create conditions for future implementations.

Although we do not have specific news to report from these markets this month, the work with our partners continues in a positive direction, with a focus on developing partnerships, strengthening market presence and preparing for future implementations.

Looking ahead – a strong position heading into spring
With the ADDA award, new growth capital to strengthen the organization and continued strong demand, we are entering the spring with good visibility.

During March, the focus will be on finalizing the ADDA process, receiving decisions in ongoing procurements, launching implementations with new municipalities in Sweden, continuing the scaling in the Netherlands and supporting our partners in other markets.

We will continue to work purposefully to make Dosell a natural part of the future of medication management.

Thank you for following our journey.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Monthly Letter February – ADDA, Growth Capital and Preparations for Scaling

AdobeStock 236999430

Dosell Awarded Framework Agreement in Sweden’s First National Procurement of Medication Dispensing Systems

iZafe Group AB (publ) announces that its subsidiary Dosell AB has been awarded a framework agreement in ADDA’s national procurement “Medication Dispensing Systems with Remote Care Platform 2025”.

This marks Sweden’s first national procurement of medication dispensing systems and remote care platforms. The framework agreement enables municipalities and regions across Sweden to procure Dosell’s solution for safe, quality-assured and efficient medication management in home care settings without conducting their own procurement processes.

According to ADDA’s procurement documentation, the estimated total annual value of the framework agreement amounts to approximately SEK 200 million. The estimate refers to the aggregated volume across all suppliers included in the framework agreement.

Dosell AB has fulfilled all administrative requirements, qualification criteria and all requirements relating to the procurement scope.

“This national procurement represents an important step toward establishing medication dispensing systems as a natural part of future healthcare and elderly care in Sweden. By consolidating the market within a national framework agreement, municipalities are given improved conditions to scale implementation, which can contribute to enhanced patient safety, reduced medication errors and more efficient use of resources within home care and community healthcare services.

It is positive for the market that multiple suppliers are included and can jointly drive development forward. For iZafe, being part of this first national framework agreement is of significant strategic importance. It provides access to a broad national market and we will now work purposefully to ensure that Dosell becomes the preferred choice for as many municipalities as possible,” says Anders Segerström, CEO of iZafe Group.

The standstill period runs until 10 March 2026. Framework agreements may be signed once the standstill period has expired.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Dosell Awarded Framework Agreement in Sweden’s First National Procurement of Medication Dispensing Systems

Självständig Medicinering Hemtjänst

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IZAFE GROUP AB

Aktieägarna i iZafe Group AB, org.nr 556762–3391 (”iZafe” eller ”Bolaget”), kallas härmed till extra bolagsstämma den 12 mars 2026 kl. 10:00 på Bolagets lokaler på David Bagares Gata 3, Stockholm. Inregistrering inleds från klockan kl. 9:30.

RÄTT ATT DELTA OCH ANMÄLAN
Aktieägare som önskar delta på bolagsstämman ska

dels vara införd i den av Euroclear Sweden AB förda aktieboken den 4 mars 2026,

dels senast den 6 mars 2026 anmäla sig för deltagande på stämman hos Bolaget via e-post till eller per post till David bagares gata 3 BV, 111 38 Stockholm, ”Bolagsstämma”. Vid anmälan ska aktieägaren uppge namn, person- eller organisationsnummer, adress, och telefonnummer samt, i förekommande fall, uppgift om biträde (högst 2).

FÖRVALTARREGISTRERADE AKTIER
Aktieägare som har låtit förvaltarregistrera sina aktier måste låta registrera sina aktier i eget namn per avstämningsdagen den 4 mars 2026 för att ha rätt att delta vid stämman. Sådan registrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner. Rösträttsregistreringar som genomförts (dvs. är registrerade hos Euroclear Sweden AB) senast den 6 mars 2026 beaktas vid framställningen av aktieboken.

OMBUD
Aktieägare som företräds genom ombud ska utfärda skriftlig, av aktieägaren undertecknad och daterad fullmakt för ombudet. Fullmaktens giltighetstid får vara högst fem år om det särskilt anges. Anges ingen giltighetstid gäller fullmakten högst ett år. Om fullmakten utfärdas av juridisk person ska kopia av registreringsbevis eller motsvarande för den juridiska personen bifogas.

Fullmakten i original samt eventuellt registreringsbevis bör i god tid före stämman insändas per brev till Bolaget på ovan angiven adress. Fullmaktsformuläret finns tillgängligt på Bolagets webbplats (www.izafegroup.com) senast tre veckor innan stämman.

FÖRSLAG TILL DAGORDNING

Stämmans öppnande
Val av ordförande vid stämman
Upprättande och godkännande av röstlängd
Godkännande av dagordningen
Val av en eller två justeringsmän
Prövning av om stämman blivit behörigen sammankallad
Beslut om godkännande av riktad nyemission av B-aktier
Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Stämmans avslutande

FÖRSLAG TILL BESLUT
Punkt 2 – Val av ordförande vid stämman
Valberedningen föreslår att stämman väljer Richard Wolf till ordförande vid bolagsstämman eller, vid förhinder, sådan annan person som styrelsen anvisar.
Punkt 7 – Beslut om godkännande av riktad nyemission av B-aktier
Styrelsen föreslår att bolagsstämman beslutar att godkänna styrelsens beslut den 19 februari 2026 att öka Bolagets aktiekapital med högst 1 961 800,70 kronor genom en riktad nyemission av högst 39 236 014 B-aktier enligt följande villkor.

Rätt att teckna nya B-aktier ska, med avvikelse från aktieägarnas företrädesrätt, tillfalla nedanstående parter.

Namn	Antal aktier
Gästrike Nord Invest AB & privat	20 000 000
Wardco Invest AB	4 000 000
Junior Farma SL	3 030 304
Björn Rosengren	606 061
Massimiliano Franzé	600 000
Erik Dahlberg	1 212 121
Rustan Panday	1 515 152
Exelity AB	8 272 376
Summa	39 236 014

Efter en samlad bedömning, och med beaktande av rådande marknadsläge, Bolagets finansiella ställning och Bolagets ägarstruktur, anser styrelsen att det på objektiva grunder ligger i Bolagets och aktieägarnas intresse att genomföra de nyemissionen enligt ovan presenterade villkor. Styrelsen har i sin bedömning gjort övervägandena nedan:
1. En företrädesemission skulle ta betydligt längre tid att genomföra, vilket därmed kan riskera att Bolaget går miste om möjligheten att anskaffa kapital som säkerställer Bolagets likviditetsbehov på kort- och medellång sikt, vilket ytterst skulle kunna försämra Bolagets finansiella och operationella flexibilitet samt begränsar möjligheten för Bolaget att investera i produktinköp samt personalrekrytering vilket begränsar Bolagets förmåga att tillvarata affärsmöjligheter.
2. Genom nyemissionen kan Bolaget diversifiera och stärka Bolagets aktieägarbas med ytterligare institutionella och andra kvalificerade investerare vilket bedöms vara fördelaktigt för Bolaget, dess långsiktiga utveckling och aktiens likviditet.
3. En företrädesemission genomförs därtill normalt till en sedvanlig, inte oväsentlig, rabatt i förhållande till rådande aktiekurs och styrelsen bedömer att en företrädesemission sannolikt skulle genomförts till en lägre teckningskurs än den som fastställts i nyemissionen, givet de rabattnivåer för företrädesemissioner som genomförts på marknaden i närtid. Det finns vidare även risk för att en negativ kursutveckling förekommer under processen, särskilt med hänsyn till de volatila och utmanande marknadsförutsättningar som råder, vilket i sin tur medför risk att en företrädesemission inte skulle tecknas i tillräcklig utsträckning och således inte tillföra Bolaget tillräckligt med kapital.
4. Mot bakgrund av rådande marknadsförutsättningar och den volatilitet som har kunnat observeras på aktiemarknaden, har styrelsen bedömt att en företrädesemission också skulle kräva betydande garantiteckning från ett garantikonsortium, vilket skulle medföra merkostnader och/eller ytterligare utspädning för aktieägarna beroende på vilken typ av vederlag som betalas ut för sådana garantiåtaganden. Styrelsen noterar även att det för närvarande råder en ökad regulatorisk osäkerhet avseende genomförandet av garantiåtaganden, vilket medför en risk att en företrädesemission inte skulle kunna säkerställas i önskvärd omfattning och därmed riskera att inte tillföra Bolaget tillräckligt kapital.
5. Skälet till att befintliga aktieägare inkluderats bland de teckningsberättigade i nyemissionen är att dessa ägare uttryckt och visat ett långsiktigt intresse för Bolaget, vilket enligt styrelsen skapar trygghet och stabilitet för både Bolaget och dess aktieägare. Styrelsen bedömer att deltagandet från befintliga aktieägare är av betydelse för ett framgångsrikt genomförande av nyemissionen.
6. Med beaktande av ovanstående har styrelsen bedömt att nyemissionen, enligt de presenterade villkoren, utgör ett bättre alternativ för såväl Bolaget som för samtliga aktieägare än en företrädesemission. Styrelsens samlade bedömning är därför att de redovisade skälen för nyemissionen överväger skälen för en företrädesemission enligt huvudprincipen och att en nyemission får anses ligga i såväl Bolagets som aktieägarnas bästa intresse. Teckning av B-aktier ska ske genom teckning på teckningslista inom två veckor från emissionsbeslutet. Styrelsen har rätt att förlänga teckningstiden.
Teckning av B-aktier ska ske genom teckning på teckningslista inom två veckor från emissionsbeslutet. Styrelsen har rätt att förlänga teckningstiden.
Betalning av tecknade B-aktier ska erläggas senast inom en vecka från teckning. Styrelsen ska ha rätt att förlänga betalningstiden.
De nya B-aktierna emitteras till en teckningskurs om 0,33 kronor per aktie, vilket innebär att Bolaget tillförs cirka 12,95 miljoner kronor före transaktionsrelaterade kostnader. Grunden för teckningskursen är aktiernas marknadsvärde med beaktande av sedvanlig emissionsrabatt, fastställd bland annat genom förhandlingar på armlängds avstånd med investerare.
Till den del teckningskursen överstiger de tidigare aktiernas kvotvärde, ska det överstigande beloppet tillföras den fria överkursfonden.
De nya aktierna medför rätt till vinstutdelning första gången på den avstämningsdag för utdelning som infaller närmast efter det att nyemissionen har registrerats hos Bolagsverket och aktierna införts i aktieboken hos Euroclear Sweden AB.
För det fall en aktieteckning är anmälningspliktig till Inspektionen för strategiska produkter (ISP) enligt lag (2023:560) om granskning av utländska direktinvesteringar, och aktietecknaren anmäler detta till Bolaget senast i samband med sin aktieteckning, ska tilldelning till denne aktietecknare vara villkorad av att ISP lämnar aktietecknarens anmälan utan åtgärd eller godkänner aktietecknarens transaktion.
Verkställande direktören, eller den styrelsen utser, ska äga rätt att vidta de smärre justeringar som kan bli erforderliga i samband med registrering av beslutet hos Bolagsverket och Euroclear Sweden AB.

Punkt 8 – Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Styrelsen föreslår att stämman bemyndigar styrelsen, den verkställande direktören eller den styrelsen i övrigt förordnar att vidta sådana smärre justeringar och förtydliganden av de på stämman fattade besluten i den utsträckning detta är erforderligt för registrering av besluten.

ÖVRIGT
Majoritetskrav
För giltigt beslut enligt förslag till beslut enligt punkt 7. krävs att det biträds av aktieägare med minst två tredjedelar (2/3) av såväl de avgivna rösterna som de aktier som är företrädda vid bolagsstämman.

Aktieägares rätt att begära upplysningar
Aktieägare har av styrelsen och den verkställande direktören rätt begära upplysningar enligt 7 kap. 32 § aktiebolagslagen avseende förhållanden som kan inverka på bedömningen av ett ärende på dagordningen. Styrelsen och den verkställande direktören ska lämna ut sådana upplysningar om styrelsen anser att det kan ske utan väsentlig skada för Bolaget.

Handlingar
Kallelsen, styrelsens fullständiga förslag till beslut, handlingar enligt 13 kap 6 § aktiebolagslagen, fullmaktsformulär samt övriga handlingar enligt aktiebolagslagen hålls tillgängliga för aktieägare hos Bolaget två veckor före stämman och sänds kostnadsfritt

till de aktieägare som begär det samt uppger sin postadress. Handlingarna kommer också publiceras på Bolagets hemsida (www.izafegroup.com), senast samma dag.

Behandling av personuppgifter
För information om hur dina personuppgifter behandlas i samband med bolagsstämman, se integritetspolicyn på Euroclear AB:s webbplats,
www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Antal aktier och röster
Det totala antalet aktier i Bolaget uppgår per dagen för denna kallelse till 370 486 350, varav 600 000 A-aktier och 369 886 350 B-aktier. Det totala antalet röster i Bolaget uppgår till 375 886 350 röster där varje A-aktie berättigar till tio (10) röster och varje B-aktie berättigar till en (1) röst.

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt SaaS-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskar risken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Bolagets Certified Adviser är DNB Carnegie Investment Bank AB. Ytterligare information finns på www.izafegroup.com

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IZAFE GROUP AB

Investor Presentation 2

iZafe Group AB has resolved on a directed share issue of class B shares of approximately SEK 19.8 million in order to accelerate the pace of sales and installations.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS, OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

The Board of Directors of iZafe Group AB (“iZafe” or the “Company”) has today (i) resolved to carry out a directed share issue of 20,868,973 class B shares pursuant to the authorization granted by the Annual General Meeting held on 28 May 2025, and (ii) resolved on a directed share issue of 39,236,014 class B shares, subject to subsequent approval by an Extraordinary General Meeting (together, the “Directed Share Issues”). Notice of the Extraordinary General Meeting will be published through a separate press release. Through the Directed Share Issues, iZafe will receive approximately SEK 19.8 million before transaction costs. The investors in the Directed Share Issues consist of a number of institutional and other qualified investors, including Meriti Ekorren Global, as well as certain existing shareholders of the Company, including Gästrike Nord Invest AB, WARDCO Invest AB, Eva Redhe, Junior Farma S.L and Exelity AB (publ). The proceeds from the Directed Share Issues are intended to finance a strengthening of the organization, which is expected to enable an increased pace of installations and sales.

The Directed Share Issues
The Board of Directors of iZafe has today resolved to carry out two directed share issues of class B shares, with deviation from the shareholders’ pre-emption rights, of a total of 60,104,987 class B shares at a subscription price of SEK 0.33 per share. The Directed Share Issues will be carried out as two separate issues, whereby the Board of Directors of iZafe has resolved on (i) a directed share issue of 20,868,973 class B shares pursuant to the authorization granted by the Annual General Meeting held on 28 May 2025 (the “First Issue”), and (ii) a directed share issue of 39,236,014 class B shares, subject to subsequent approval by an Extraordinary General Meeting planned to be held on or around 12 March 2026 (the “Second Issue”). Notice of the Extraordinary General Meeting will be published through a separate press release. Through the Directed Share Issues, iZafe will receive approximately SEK 19.8 million before transaction costs. The Directed Share Issues are subscribed for by a number of existing long-term shareholders, including Gästrike Nord Invest AB, WARDCO Invest AB, Eva Redhe, Junior Farma S.L and Exelity AB (publ), as well as a number of external qualified investors, including the institutional investor Meriti Ekorren Global.

The subscription price in the Directed Share Issues has been determined through arm’s length negotiations with the investors and corresponds to a discount of approximately 10.6 per cent compared to the volume-weighted average price (VWAP) of the Company’s share on Nasdaq First North during the ten most recent trading days up to and including 18 February 2026.

The First Issue
The Board of Directors of the Company has today resolved on the First Issue of 20,868,973 class B shares at a subscription price of SEK 0.33 per share, pursuant to the authorization granted by the Annual General Meeting held on 28 May 2025. The subscribers in the First Issue comprise a number of external qualified investors and existing shareholders.

The Second Issue
The Board of Directors of the Company has also today resolved on the Second Issue, which is subject to subsequent approval by an Extraordinary General Meeting, as it is not covered by the existing issue authorization granted by the Annual General Meeting held on 28 May 2025. The Second Issue comprises a total of 39,236,014 class B shares at a subscription price of SEK 0.33 per share. The subscribers in the Second Issue comprise a number of external qualified investors and existing shareholders.

Background and rationale for the Directed Share Issues
iZafe is in a growth phase and at the beginning of 2025, in connection with the Company communicating its forecast, the Company’s ARR amounted to approximately SEK 1.7 million. At the beginning of 2026, ARR amounts to approximately SEK 10 million, in line with the previously communicated development trajectory. The Company has thereby established a stable base of recurring revenues.

Since the forecast was communicated, the business structure has been further strengthened. In the Netherlands, the previous distributor has been acquired and operations are now conducted in-house. In Sweden, the share of direct sales has increased. This means that the Company today receives a larger share of the recurring revenue per installed unit than what formed the basis for the previous forecast, which improves long-term earnings capacity. At the same time, the Company continues to develop its partner strategy in international markets. During 2026, increased activity is expected via partners in Iceland, Norway, Finland and Spain, while concrete opportunities have been identified in the United Kingdom and Denmark. The partner strategy is an important complement to direct sales and enables cost-efficient expansion into new markets.

In light of the improved earnings capacity per unit and a growing customer base consisting of more than 30 municipalities/customers in Sweden and 29 active customers in the Netherlands, the Board of Directors assesses that the Company’s long-term revenue potential is greater than what has previously been reflected in the forecast.

In order to enable accelerated growth and realize this potential, the Company intends to strengthen the organization through approximately seven key recruitments within implementation, training, sales and product development in Sweden and the Netherlands, including a Country Manager in the Netherlands. A strengthened organization is assessed to be crucial to increase the installation rate, improve onboarding of new customers and strengthen competitiveness in larger tenders.

Against this background, the Board of Directors of iZafe has resolved to carry out the Directed Share Issues in order to enable this accelerated growth and strengthen the Company’s position in a rapidly growing European market for digital medication management.

Potential impact on ARR and active Dosell units as a result of the Directed Share Issues
The Company assesses that the Directed Share Issues provide the Company with prerequisites to further increase the pace of sales and installations, provided that the Company’s expansion plans, recruitments and organizational changes can be implemented successfully and according to plan. The Company will continuously monitor the fulfilment of its forecast regarding ARR and active Dosell units and publish any revisions to the forecast in connection with quarterly reports, or if a need arises.

Deviation from shareholders’ pre-emption rights
The Board of Directors has carefully considered alternative financing options, including the possibility of carrying out a rights issue. The Board of Directors is aware that cash issues as a main rule should be conducted as rights issues and has taken into account the guidelines issued by the Swedish Securities Council’s self-regulatory committee (ASK).

Following an overall assessment, and taking into account the prevailing market conditions, the Company’s financial position and the Company’s shareholder structure, the Board of Directors considers that, on objective grounds, it is in the interest of the Company and its shareholders to carry out the Directed Share Issues on the terms presented above. In its assessment, the Board of Directors has considered, inter alia, the following:

i) A rights issue would take significantly longer to execute, which may risk the Company missing the opportunity to raise capital that secures the Company’s liquidity needs in the short to medium term, which could ultimately impair the Company’s financial and operational flexibility and limit the Company’s ability to invest in product purchases and recruit personnel, thereby limiting the Company’s ability to capitalize on business opportunities.

ii) Through the Directed Share Issues, the Company can diversify and strengthen the Company’s shareholder base with additional institutional and other qualified investors, which is considered beneficial for the Company, its long-term development and the liquidity of the share.

iii) A rights issue is also normally carried out at a customary, not insignificant, discount to the prevailing share price, and the Board of Directors assesses that a rights issue would likely have been carried out at a lower subscription price than the price determined in the Directed Share Issues, given the discount levels in rights issues carried out in the market recently. Furthermore, there is a risk of negative share price development during the process, particularly in light of the volatile and challenging market conditions, which in turn entails a risk that a rights issue would not be subscribed to a sufficient extent and thus would not provide the Company with sufficient capital.

iv) In light of current market conditions and the volatility observed in the stock market, the Board of Directors has assessed that a rights issue would also require significant underwriting commitments from an underwriting syndicate, which would entail additional costs and/or further dilution for shareholders depending on the type of compensation paid for such underwriting commitments. The Board of Directors also notes that there is currently increased regulatory uncertainty regarding the execution of underwriting commitments, which entails a risk that a rights issue could not be secured to the desired extent and thereby risk not providing the Company with sufficient capital.

v) The reason why existing shareholders have been included among the subscribers in the Directed Share Issues is that these shareholders have expressed and demonstrated a long-term interest in the Company, which, according to the Board of Directors, creates security and stability for both the Company and its shareholders. The Board of Directors assesses that participation from existing shareholders is of importance for a successful implementation of the Directed Share Issues.

Taking the above into account, the Board of Directors has assessed that the Directed Share Issues, on the presented terms, constitute a better alternative for both the Company and all shareholders than a rights issue. The Board of Directors’ overall assessment is therefore that the stated reasons for the Directed Share Issues outweigh the reasons for a rights issue under the main principle and that the Directed Share Issues are deemed to be in the best interest of both the Company and its shareholders.

The subscription price has been resolved by the Board of Directors following arm’s length negotiations between the Company and the investors. The Board of Directors assesses that the Directed Share Issues have been carried out on market terms and that the subscription price correctly reflects prevailing market conditions and demand.

Number of shares, share capital and dilution
If all class B shares in the Directed Share Issues are subscribed for, the number of shares and votes in the Company will increase by 60,104,987 from 370,486,350 shares (of which 600,000 are class A shares) to 430,591,337 shares (of which 600,000 are class A shares), corresponding to an increase in the share capital by SEK 3,005,249.35 from SEK 18,524,317.50 to SEK 21,529,566.85. Of the increase in the share capital, SEK 1,043,448.65 is attributable to the First Issue and SEK 1,961,800.70 is attributable to the Second Issue. The Directed Share Issues entail a dilution of approximately 13.96 per cent of the Company’s share capital. The dilution effect is calculated as the number of new shares issued through the Directed Share Issues divided by the total number of shares in the Company after the Directed Share Issues.

Subsequent approval at the Extraordinary General Meeting
The Board of Directors’ resolution on the Second Issue is subject to subsequent approval by an Extraordinary General Meeting planned to be held on or around 12 March 2026. Notice of the Extraordinary General Meeting will be published through a separate press release. Shareholders representing approximately 45 per cent of the votes in the Company have expressed their intention to vote in favor of approving the Second Issue.

Advisers
Nordicap Corporate Finance AB acts as financial adviser and LegalWorks acts as legal adviser to iZafe in connection with the Directed Share Issues. Aqurat Fondkommission AB acts as issuing agent in connection with the Directed Share Issues.

Important information
The publication, release or distribution of this press release may be subject to restrictions under law in certain jurisdictions, and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each relevant jurisdiction. This press release does not constitute an offer to sell, or a solicitation of an offer to acquire or subscribe for, any securities issued by the Company in any jurisdiction where such offer or solicitation would be unlawful or would require registration or any other measures.

This press release does not constitute an offer to, or solicitation of an offer to acquire or subscribe for, securities in the United States. The securities referred to herein may not be sold in the United States absent registration, or an exemption from registration, under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration, an exemption from registration, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any of the securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Japan, Canada or any other jurisdiction where such announcement, publication or distribution of this information would be in violation of applicable rules or where such measures are subject to legal restrictions or would require registration or other measures in addition to those required under Swedish law. Actions taken in violation of this instruction may constitute a violation of applicable securities laws.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of securities in any EEA member state and no prospectus has been prepared, or will be prepared, in connection with the issue. In any EEA member state, this communication is only addressed to “qualified investors” in that member state as defined in the Prospectus Regulation.

In the United Kingdom, this document and any other material in relation to the securities referred to herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (within the meaning of section 86(7) of the UK Financial Services and Markets Act 2000) who are (i) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within article 49(2)(a)-(d) of the Order (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this press release and should not act or rely on it.

This press release does not identify or purport to identify all risks (direct or indirect) that may be associated with an investment in the Company’s shares. Any investment decision to acquire or subscribe for new shares in the issue must be made solely on the basis of publicly available information regarding the Company and the Company’s shares. Such information has not been independently verified by Nordicap Corporate Finance AB (“Nordicap”). Nordicap is acting for the Company in connection with the issue and not for anyone else. Nordicap will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Directed Share Issues or any other matter referred to herein.

This press release does not constitute a recommendation regarding any investor’s decision relating to the issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and the information described in this press release and all publicly available information. The price and value of securities may decrease as well as increase. Past performance is not a guide to future performance. Neither the contents of the Company’s website nor any other website accessible through hyperlinks on the Company’s website are incorporated into, or form part of, this press release.

Failure to comply with these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions.

Forward-looking statements
This press release contains forward-looking statements relating to the Company’s intentions, assessments or expectations regarding the Company’s future results, financial condition, liquidity, development, prospects, expected growth, strategies and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and may be identified by the use of expressions such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “assumes”, “should”, “could” and, in each case, their negatives, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Even though the Company believes that the assumptions reflected in these forward-looking statements are reasonable, it cannot be guaranteed that they will occur or that they are correct. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what is set out in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct and each reader of the press release should not unduly rely on the forward-looking statements herein. The information, opinions and forward-looking statements expressly or impliedly contained herein are only given as of the date of this press release and are subject to change. Neither the Company nor any other person undertakes any obligation to review, update, confirm or publicly announce any revisions to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, except as required by law or by Nasdaq’s rulebook.

Information to distributors
Solely for the purposes of the product governance requirements contained in: (a) Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) national implementing measures (together the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (within the meaning of the MiFID II Product Governance Requirements) might otherwise have, the Company’s shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an identified target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II (the “Positive Target Market”); and (ii) compatible with distribution through all distribution channels as permitted by MiFID II. Distributors should note that: the price of the Company’s shares may decline and investors could lose all or part of their investment; the Company’s shares offer no guaranteed income and no capital protection; and an investment in the Company’s shares is compatible only for investors who do not need a guaranteed income or capital protection and who (either alone or with the help of an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and have sufficient resources to be able to bear any losses that may result from such an investment. Conversely, an investment in the Company’s shares is not compatible for investors who need full capital protection or full repayment of the amount invested, cannot bear any risk or who require guaranteed or predictable returns (the “Negative Target Market”, and together with the Positive Target Market, the “Target Market”). The target market assessment is without prejudice to any other requirements regarding contractual, legal or regulatory selling restrictions in relation to the issue. Furthermore, it should be noted that notwithstanding the target market assessment, Nordicap will only provide investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the target market assessment does not constitute (a) an appropriateness or suitability assessment within the meaning of MiFID II, or (b) a recommendation to any investor or group of investors to invest in, acquire, or take any other action whatsoever in relation to the Company’s shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Company’s shares and determining appropriate distribution channels.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has resolved on a directed share issue of class B shares of approximately SEK 19.8 million in order to accelerate the pace of sales and installations.

Business Partners

iZafe Group’s Quarterly Report Q4, October–December 2025

iZafe Group AB (publ.) today, February 16, publishes its report for the fourth quarter.

Financial Performance in Summary

The Group’s total net sales for the quarter amounted to 2,435 TSEK (2,345) and consisted entirely of recurring license revenues, with no hardware sales during the period. This is in contrast to the corresponding quarter of the previous year, when revenues were largely derived from hardware sales. The development demonstrates that iZafe Group has now established a business model focused on recurring revenues. During the quarter, the Group also began consolidating revenues from the Dutch operations, contributing to net sales and strengthening the recurring revenue base. At the beginning of 2026, the Group’s annual recurring revenue (ARR) amounted to approximately 10 MSEK, in line with the Company’s previously communicated target.
Operating result (EBIT) for the quarter amounted to -5,714 TSEK (-5,679).
Earnings before depreciation and amortization (EBITDA) for the quarter amounted to -3,888 TSEK (-4,174). The result represents an improvement compared to the previous year but was during the quarter impacted by the consolidation of the Dutch operations as well as increased investments to support the positive business development and continued growth.
Result after financial items for the quarter amounted to -4,971 TSEK (-5,908).
Cash flow from operating activities for the quarter amounted to -2,940 TSEK (-178).
Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
Equity per share at the end of the period amounted to 0.03 SEK (0.04).
The equity ratio at the end of the period was 32.8% (40.1%).

Significant events during the quarter

iZafe Group AB (publ.) has entered into a distribution agreement with Skand ehf regarding the launch and sale of the Dosell medication dispensing device in Iceland. The agreement represents a step in the Company’s Nordic expansion and entails that Dosell is established in an additional European market. As part of the agreement, Skand ehf has placed an initial order of 300 Dosell units with planned delivery during 2026, which, once fully activated, is expected to generate annual recurring revenue (ARR) of approximately 2–3 MSEK.
iZafe Group AB (publ.) has entered into a strategic partnership with Vakt og Alarm AS regarding the distribution, installation and support of the Dosell medication dispensing device in Norway. As an initial outcome of the collaboration, the parties have jointly won a public procurement covering six municipalities and an initial volume of approximately 100 Dosell units. The agreement is planned to enter into force on 1 February 2026 following the expiry of the standstill period.
iZafe Group AB (publ.) announces that all participants in the Company’s long-term incentive program, LTIP 2023, have exercised their Series A warrants for subscription of shares in the Company. Through the exercise, the Company receives subscription proceeds of approximately 0.26 MSEK and the number of Class B shares increases by 5,271,918, corresponding to a dilution

Significant events after the end of the quarter

iZafe Group AB (publ.) has launched a modular external Display for Dosell as well as a new remote care system with a web interface and mobile application. The launch means that Dosell is further developed into a more flexible and scalable solution that can be adapted to different user needs. The Display and the remote care system are planned to be made available gradually during 2026, and the commercial impact will depend on customer needs, procurement processes and the pace of implementation.

FORECAST
In this report, we present a forecast chart illustrating our expected growth in both ARR and active Dosell units in the coming years. The forecast is based on our current markets and key metrics and shows a clear path toward continued strong growth in recurring revenues as more units are activated.

At the beginning of 2026, our ARR amounted to approximately SEK 10 million, representing an increase of 488 percent compared with the previous year. During 2026, this growth is expected to accelerate further, with ARR forecasted to reach SEK 22.5 million by year end, an increase of 125 percent. We will follow up on this forecast quarterly to provide you as shareholders with a clear picture of our actual development and how we are progressing toward our financial targets.

	2023	2024	2025	2026	2027	2028	2029
ARR (MSEK)	0.3	1.7	10	22.5	42.3	63.9	85.5
Growth of Dosells	0 %	326 %	352 %	125 %	69 %	41 %	29%

Comments from the CEO
2025 has been the year in which iZafe Group firmly established its scalable business model. The fourth quarter confirms this in the numbers. Net sales for the quarter amounted to 2,435 TSEK and consisted entirely of recurring license revenues. We have thereby transitioned from a period in which hardware deliveries dominated revenue to a business now fully driven by subscription-based income.

We enter 2026 with approximately 10 MSEK in annual recurring revenue, in line with our previously communicated forecast for the fourth quarter. This marks an important milestone in the Company’s development and demonstrates that our strategy is delivering results.

Today, we are a company fully focused on building annual recurring revenue (ARR). First, we deploy our units with customers. Thereafter, a stable ARR base develops, generating margins and long-term predictable earnings.

A growing customer base with built-in scalability
Today, we have more than 30 municipalities in Sweden and 29 active customers in the Netherlands. Sweden and the Netherlands are our two prioritized core markets and represent significant growth potential going forward. Our established customer base provides a stable and scalable platform for continued expansion.

Nordic and international expansion
During the quarter, we further strengthened our Nordic presence through new partnerships in Norway, Iceland and Finland. These are important steps that confirm the scalability of our model beyond our original markets.

In the Netherlands, we have fully integrated the operations following the acquisition of our former distributor. This provides improved control, a higher revenue share per unit and a clearer growth platform. In 2026, we plan to continue investing in the Dutch organization to accelerate development in the Dutch market, which is the largest in Europe in terms of the use of dose-dispensed medication pouches.

We see clear and growing interest across several European countries for secure and connected solutions for medication management in the home. Our position continues to strengthen through both partnerships and direct market presence.

Product development driving competitiveness
Dosell continues to evolve in line with our growth, which is essential to meet increasing customer requirements and strengthen our market position. After the end of the reporting period, we launched a modular external Display for Dosell as well as a new remote care system with a web interface and mobile application. This makes Dosell more flexible and adaptable to different user needs. With this launch, Dosell together with the remote care system has achieved MDR Class I compliance, strengthening our competitiveness in public procurements and larger contracts.

Outlook and the road ahead
The forecast previously communicated remains unchanged. With an entry level of approximately 10 MSEK in ARR, we enter 2026 with a stable and growing base.

During 2026, we will focus both on expanding our customer base and on increasing the penetration rate among existing customers. While we have won several new customers, the real leverage arises when we increase the number of active units within existing municipalities and customer organizations. As Dosell demonstrates clear value in daily operations, we see usage gradually expand, where customer satisfaction drives both higher penetration and new business opportunities through references and procurements.

An important factor during 2026 is the ongoing ADDA procurement process. The outcome has not yet been communicated, but we see significant strategic value in Dosell potentially becoming part of the framework agreement. Such an outcome would further strengthen our position in the Swedish market and facilitate adoption for a large number of municipalities. However, our current forecast does not include this agreement.

We are operating in a strong phase of development. Our business model is established. Our recurring revenues are growing. Our customer base continues to expand. Our product platform is broader, more flexible and better positioned for continued growth.

We have laid the foundation. In 2026, we continue to scale.

I would like to extend my sincere thanks to our employees, partners and shareholders for your continued trust. The journey continues, and we enter 2026 with focus, structure and a clear ambition for growth.

Anders Segerström
Chief Executive Officer, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Interim Report Q4 2025

Q4 2025 CEO interview

Q4 2025

Monthly Update January – Broad Momentum and the Launch of a New Platform

2026 has kicked off with continued high pace and several important developments in both the Swedish and international markets. With many parallel initiatives and rollouts underway, we are strengthening our presence, deepening partnerships, and continuing to build for broader deployment of Dosell, with an even greater focus on scalability and flexibility.

We enter the year with a strong pipeline, an increasing number of inbound requests, and the launch of our new remote care system and display solution – which has been very well received.

Sweden – Growing demand, more procurements, and continued expansion
In Sweden, both interest and market maturity continue to grow. We are now seeing several parallel procurements in addition to the national ADDA tender, a clear indication that medication dispensers have become an integrated part of future healthcare. Several municipalities are also referring to the joint digitalization initiative Handslaget from SKR, which promotes broad implementation of proven welfare technologies – a movement in which Dosell is perfectly aligned.

We continue to maintain strong dialogue with both new and existing municipalities. While lead times are often long due to necessary processes, risk assessments, and anchoring, we are well positioned in many of these. In January, several new quotes and agreement proposals were sent out, and one of our existing customers has already placed a new order for 40 units, along with 15 of our newly launched displays for greater flexibility.

We also conducted five additional digital demonstrations in January and continue to receive new inquiries on an ongoing basis.

The tender submission for Sweden’s first national framework agreement for medication dispensers via ADDA was completed on time by January 5. We also participated in a bid presentation and expect feedback in February. Several municipalities have already signaled their intention to procure Dosell as soon as the agreement is in place.

At the MVTe fair in Stockholm, we launched our remote care platform together with our new modular display. This unique solution makes it possible to use Dosell even for patients who previously could not benefit from a medication dispenser – for example, due to cognitive impairment or a need for more visual guidance.

The response has been very positive. Several municipalities have already requested quotes for the full solution, and we see this as an important complement that can further broaden the target group and increase the value per unit.

Norway – From contract to implementation
Our partnership with Vakt og Alarm has now entered the next phase. The procurement we won with six municipalities began as planned on February 1, and the focus is now on training and implementation. We estimate the initial rollout to include around 100 units and look forward to tracking its progress together with our partner.

The Netherlands – Growth and customer satisfaction
In the Netherlands, our development continues steadily. In January, we signed scale-up agreements with several existing customers and conducted joint evaluations of the implementations. All evaluations confirm high satisfaction, which is also reflected in our latest customer survey: 82.5% of users report being satisfied or very satisfied and would recommend Dosell to others. Several concrete improvement suggestions have been received and are now being implemented.

We have also been contacted by several new potential clients and are engaged in active discussions for pilots and future rollouts. The structural tailwind in the Netherlands is clear – medication dispensers are on their way to becoming the norm in home care, and demand is growing rapidly.

We consider the Netherlands one of our most important markets in Europe. The country has approximately 600,000 patients who receive their medications in dose rolls, compared to around 300,000 in Sweden, which represents a target group twice the size. Additionally, the time from decision to actual implementation is often much shorter than in other countries, offering strong potential for faster growth.

In 2026, we are investing aggressively in the Netherlands by strengthening our local presence. The recruitment of a dedicated Country Manager is in its final stages, with the goal of building a strong local team and scaling the business in pace with sales.

Dosell has also now been approved for inclusion on Digizo.nu – the Dutch national program focused on the broad implementation of proven digital and hybrid care solutions. The program helps healthcare organizations identify effective, validated technologies that deliver real value for patients, users, and professionals. Being listed on Digizo.nu serves as a quality mark, streamlining adoption among new clients and increasing our visibility with both public and private care providers throughout the country.

Iceland – Early-stage groundwork
Preparatory work is underway for a potential market entry in Iceland, where our local partner is engaged in discussions with key stakeholders in both the pharmacy and municipal sectors. There is growing interest in Dosell, and the Icelandic market is characterized by clear national structures, which creates good conditions for coordinated implementation over time.

WHX in Dubai
We are currently participating in the World Health Expo (WHX) in Dubai – the world’s largest healthcare exhibition. The aim of our participation is to meet potential partners and distributors, network with international stakeholders, and identify new opportunities for further expansion.

Looking Ahead – An exciting 2026 has only just begun
We are starting the year with strong momentum and clear visibility. With new markets, stronger solutions, more implementations, and strategic collaborations in place, our focus now is to turn these opportunities into concrete growth. In February, we are prioritizing:

Securing additional agreements
Awaiting ADDA allocation decisions
Starting several planned implementations in February and March
Continued follow-ups in Norway, Spain, Iceland, and Finland

Thank you for following our journey!

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Monthly Update January – Broad Momentum and the Launch of a New Platform

1770126149070

iZafe Group launches modular Display and remote care system – one Dosell for all users

iZafe Group AB (“Company”) today launches an external Display for Dosell together with a new remote care system featuring a web interface and mobile app. The launch takes place in connection with the MVTe trade fair, which starts today, where Dosell is exhibiting at booth I24. The new solution means that healthcare providers no longer need to choose between simpler or more advanced medication dispensing devices – the same Dosell can now be used for all users and complemented with a Display when additional functionality is needed.

The new Display is a modular add-on that enables Dosell’s functionality to be scaled over time. The Display can be mounted directly on Dosell, placed next to the unit, or used completely standalone, even in another room. When the Display is not required, Dosell can be used as a standalone solution, and when needs change, the Display can easily be added or removed.

This allows municipalities and care providers to standardize on a single medication dispensing device while adapting the level of functionality to individual user needs. For users who require additional support, the Display can provide clear information on upcoming doses, reminders for other medications, and the option for video calls with care staff. For other users, Dosell in its base configuration is sufficient.

At the same time, iZafe is launching a new remote care system that brings administration, monitoring, and communication together in a unified digital platform. Through a web-based administration interface, care organizations gain an overview of all Dosell units, alarms, events, historical data, adherence information, and user and access management with full traceability and logging. The system is complemented by mobile app and web access, enabling authorized staff to securely access assigned Dosell units, view upcoming doses, manage alarms, review history, and conduct video calls.

Video calls enable a new and more flexible way of working with medication management. In certain situations, medication intake can take place in connection with a video call, allowing care staff to visually confirm that the medication is taken. This is a selectable support function, intended for cases where increased supervision and reassurance are needed.

“With this launch, we remove a common trade-off in medication dispensing – choosing between simpler or more advanced devices. Instead, we offer a flexible solution where the same Dosell can be used for all users and complemented with a Display as needs evolve. This gives municipalities and care providers a completely different level of long-term efficiency and adaptability,” says Anders Segerström, CEO of iZafe Group AB.

The launch marks a strategic step in the evolution of Dosell from a standalone product into a modular platform that can be adapted over time. The solution supports different levels of supervision and independence and aligns with the ongoing shift toward increased remote care and more efficient use of resources in healthcare and social care.

More information about the Display and the new remote care system is available at:
https://display.dosell.com/

The Display and the remote care system will be made available gradually during 2026, initially as optional add-ons, in new deliveries, and through pilot projects in selected markets. Additional functionality is planned to be introduced continuously.

This is a technical and functional product launch. Commercial impact will depend on customer needs, procurement processes, and implementation pace.

iZafe Group is exhibiting at the MVTe trade fair at booth I24 and welcomes visitors who wish to experience the solution firsthand.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group launches modular Display and remote care system – one Dosell for all users

Dosell Produkter+app